Evaluation of the CLL-IPI in Relapsed and Refractory Chronic Lymphocytic Leukemia in Idelalisib Phase 3 Trials

The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with relapsed/refractory CLL in 3 randomized trials test...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leuk Lymphoma
Auteurs principaux: Soumerai, Jacob D., Ni, Ai, Xing, Guan, Huang, Julie, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., Hallek, Michael, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah, Zelenetz, Andrew D.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545166/
https://ncbi.nlm.nih.gov/pubmed/30407886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1540782
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires